The American Journal of Managed Care10d
Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
JD Supra1mon
FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba)
On December 18, 2024, Celltrion announced that the FDA has approved its ustekinumab biosimilar, STEQEYMA (ustekinumab-stba), referencing Jannsen’s STELARA. STEQEYMA is approved for subcutaneous ...
JD Supra1mon
Recent Ustekinumab and Denosumab Biosimilars Deals
On Dec 24, 2024, Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, a proposed ustekinumab biosimilar to Jansen’s ...
The American Journal of Managed Care11d
Psoriasis Treatment Remains Effective, Safe After Switch From Ustekinumab to Biosimilar SB17
Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...
Nature1mon
Is ustekinumab superior to etanercept for psoriasis?
Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...
Newswire1mon
Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfi™* an Ustekinumab Biosimilar
TORONTO, Jan. 8, 2025 /CNW/ - Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for Otulfi TM, an ustekinumab biosimilar indicated for Crohn's disease ...